Last reviewed · How we verify
NCT06920706
Efficacy of Remote Ischemic Conditioning in Preventing Post-Stroke Depression
NA trial testing RIC in Post-stroke Depression in 240 participants. Not yet recruiting.
31 December 2026
Quick facts
| Lead sponsor | Xuanwu Hospital, Beijing |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | prevention |
| Enrollment | 240 |
| Start date | 10 April 2025 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 5 locations across China |
Drugs / interventions tested
- RIC
- Sham-RIC
Conditions studied
- Post-stroke Depression — all drugs for Post-stroke Depression →
- Remote Ischemic Conditioning — all drugs for Remote Ischemic Conditioning →
Sponsor
Xuanwu Hospital, Beijing
Who can join
18 and older, any sex, with Post-stroke Depression or Remote Ischemic Conditioning. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Post-stroke depression (PSD) is characterized primarily by low mood and loss of interest following a stroke. It is one of the most common and serious complications of stroke, with an incidence of 11% to 41% within two years post-stroke. PSD significantly impacts stroke prognosis, not only hindering neurological recovery but also increasing clinical disability and mortality rates, thereby imposing substantial economic and psychological burdens on families and society. Therefore, preventing PSD is crucial for stroke rehabilitation. Clinical trials have demonstrated that preventive antidepressant treatment can reduce PSD incidence and improve clinical outcomes; however, controversies remain regarding the timing, methods, and safety. Meanwhile, preventive psychological therapy faces challenges in implementation due to effectiveness, accessibility, and cost-effectiveness. Remote ischemic preconditioning (RIC) is a non-invasive, cost-effective, and non-pharmacological intervention. By modulating small molecules in the peripheral and central nervous systems through transient, periodic limb blood flow restriction and reperfusion, RIC reverses neurobiological changes and demonstrates neuroprotective potential in various neurological diseases. Recently, a study showed that RIC is safe and effective in preventing PSD; however, the sample size is small and the specific mechanisms remain unclear. Therefore, this study aims to further explore the role and mechanisms of RIC in PSD prevention.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
A perspective on the potential role of remote ischemic conditioning in post-stroke depression: Mechanisms and future directions.
Zhang H, Shao R, Wan S, Liao S, et al · · 2026 · PMID 41816873 · DOI 10.1177/0271678x261426923
Verify or expand the search:
- PubMed search for NCT06920706
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of RIC
Trials testing the same drug.
- NCT06178419 — Remote Ischemic Conditioning for Cerebral Ischemia in Patients With Takayasu Arteritis (TARIC-1) · NA · recruiting
- NCT05470491 — Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Foll · Phase 1, PHASE2 · recruiting
- NCT05426707 — Remote Ischemic Conditioning for the Treatment of Resistant Hypertension · NA · unknown
- NCT04012268 — The Safety and Efficacy of RIC on Adult Moyamoya Disease · NA · completed
- NCT03922724 — Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma · Phase 2 · recruiting
Other recruiting trials for Post-stroke Depression
Currently open trials in the same condition.
- NCT07294274 — Construction and Clinical Validation Study of a Prediction Model for Depression After Ischemic Stroke · recruiting
- NCT06598670 — Transcranial Direct Current Stimulation on Post Stroke Depression · NA · recruiting
Other Xuanwu Hospital, Beijing trials
Trials by the same sponsor.
- NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
- NCT07519044 — Safety and Efficacy of Adjunctive GM1 to Mechanical Thrombectomy for Acute Anterior Circulation Large Vessel Occlusion · Phase 4 · not yet recruiting
- NCT07396077 — Pre-operative Risk Assessment Combined With Targeted Intervention in the Chinese Elderly With Spine Surgery II · NA · not yet recruiting
- NCT07457125 — The Effect of CB-Exo-A600 in Mild to Moderate Alzheimer's Disease · Phase 1, PHASE2 · not yet recruiting
- NCT07479446 — Oliceridine Versus Sufentanil for Postoperative Nausea in Cerebellopontine Angle Surgery · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06920706 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xuanwu Hospital, Beijing
- Last refreshed: 10 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06920706.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing